Microchip Technology Inc
Change company Symbol lookup
Select an option...
MCHP Microchip Technology Inc
OSUR OraSure Technologies Inc
QUOT Quotient Technology Inc
DUK Duke Energy Corp
WAFD Washington Federal Inc
REML Credit Suisse X-Links Monthly Pay 2xLeveraged Mortgage REIT ETN
$NQG3010LMT Nasdaq Global Banks Large Mid Cap To
SRTS Sensus Healthcare Inc
LITB LightInTheBox Holding Co Ltd
MZA BlackRock MuniYield Arizona
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Company profile

Microchip Technology Incorporated is engaged in developing, manufacturing and selling specialized semiconductor products used by its customers for a range of embedded control applications. The Company operates through two segments: semiconductor products and technology licensing. In the semiconductor products segment, the Company designs, develops, manufactures and markets microcontrollers, development tools and analog, interface, mixed signal and timing products. Its functional activities include sales, marketing, manufacturing, information technology, human resources, legal and finance. Its product portfolio comprises general purpose and specialized 8-bit, 16-bit, and 32-bit microcontrollers, a spectrum of linear, mixed-signal, power management, thermal management, radio frequency (RF), timing, safety, security, wired connectivity and wireless connectivity devices, as well as serial electrically erasable programmable read-only memories (EEPROMs) and serial flash memories.

Premarket

Last Trade
Delayed
$100.70
1.65 (1.67%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$99.05
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
156

10-day average volume:
1,871,532
156

Novus Therapeutics stock loses nearly half its value after disappointing drug trial results

9:50 am ET June 1, 2020 (MarketWatch)
Print

Shares of Novus Therapeutics Inc. (NVUS) lost nearly half their value in active trading Monday, after the specialty drug maker announced disappointing trial results of its ear infection treatment. Trading volume spiked to 5.3 million shares, well above the full-day average of about 953,000 shares, as the stock plunged 46%. The company said a phase 2a trial of OP0201 in acute otitis media did not achieve statistical significance in achieving its primary targets for results. The company said, however, it was encouraged by the statistical trend that favored the OP0201 treatment group with regard to middle ear effusion. Separately, Novus said it has starting exploring options to maximize shareholder value, including engaging Ladenburg Thalmann as financial advisor. The options could include a financing to continue developing its surfactant-based nasal aerosol, a sale of the company or assets, or other deals. Despite the stock's selloff, it has still gained 17% year to date, while the S&P 500 has lost 5.8%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 01, 2020 09:50 ET (13:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.